摘要
目的探讨新辅助化疗对乳腺癌组织中人类表皮生长因子受体-2(HER-2)、细胞增殖核抗原Ki-67(Ki-67)表达的影响及其临床意义。方法采用免疫组化SP法,检测120例乳腺癌患者新辅助化疗前后乳腺癌组织中HER-2、Ki67表达。结果120例患者中临床RR为76.66%。新辅助化疗前后HER-2的阳性表达率,差异无统计学意义(P>0.05);新辅助化疗后Ki-67的高表达率显著低于化疗前(P<0.05)。新辅助化疗前HER-2阳性表达患者的新辅助化疗疗效显著优于阴性表达患者(P<0.05);新辅助化疗前Ki-67高表达患者的新辅助化疗疗效显著优于低表达患者(P<0.05)。结论新辅助化疗对HER-2的表达无显著影响,新辅助化疗能改变乳腺癌患者Ki-67的表达情况。HER-2和Ki-67可以作为预测新辅助化疗疗效的生物标志物。
Objective To discuss the Effect of neoadjuvant chemotherapy on human epidermal growth factor receptor-2(HER-2)and Nuclear-associated antigen Ki-67(Ki-67)expression in breast cancer and its significance.Methods The expression of the HER-2 and Ki-67 in 120 patients with breast cancer were examined by immunohisto-chemical as say before and after neoadjuvant chemotherapy.Results The clinical response rate in 120 patients was 76.66%.Pre and post neoadjuvant chemotherapy,positive expression rate of HER-2 showed no significant changes(P<0.05);After neoadjuvant chemotherapy,the high expression rate of Ki-67 was significantly decreased(P<0.05).Patients with positive expression of HER-2 responded well to neoad-juvant chemotherapy(P<0.05);Patients with high expression of ki-67 responded well to neoad-juvant chemotherapy(P<0.05).Conclusion NAC has no effect on the status of HER-2,NAC can change the status of Ki-67.HER-2 and Ki-67 can be used as biomarkers for predicting the efficacy of neoadjuvant chemotherapy.
作者
王西礼
WANG Xili(Kaifeng Central Hospital,Kaifeng,475000)
出处
《实用癌症杂志》
2019年第8期1345-1347,共3页
The Practical Journal of Cancer
基金
河南省科技攻关计划项目(编号:162102310320)
